RecruitingMetastatic Lobular Breast Carcinoma
[68Ga]Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Eligible age
18–89 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a prospective study using \[68Ga\]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic/advanced invasive lobular breast cancer (LBC).
Sponsor: University of California, Davis
You may qualify if…
- ✓ (Ability to understand and willingness to sign a written informed consent document.
- ✓ Men and women age ≥ 18 yrs
- ✓ Confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1) or PERCIST
- ✓ Available archival tumor tissue
- ✓ Eastern Cooperative Oncology Group Performance Status ≤ 2
- ✓ Hematologic parameters defined as: Absolute neutrophil count (ANC) ≥ 1000 cells/mm3,Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 8 g/dL.
- ✓ Blood chemistry levels defined as: AST, ALT, alkaline phosphatase ≤ 5 times upper limit of normal (ULN), Total bilirubin ≤ 2 times ULN, eGFR \>60 mL/min/1.73m\*2
- ✓ Anticipated life expectancy ≥ 3 months
You may not qualify if…
- ✕ Pregnant and lactating women
- ✕ Prisoners
- ✕ Concurrent malignancy of a different histology that could confound imaging interpretation.
- ✕ Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)
Where it's recruiting
California
Sacramento
Source: ClinicalTrials.gov · NCT07020806 · last updated 2026-03-23